| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:37 UTC |
|---|
| HMDB ID | HMDB0014426 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Lidocaine |
|---|
| Description | Lidocaine is only found in individuals that have used or taken this drug. It is a local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. [PubChem]Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na+) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anaesthetic effect by not merely preventing pain signals from propagating to the brain but by aborting their birth in the first place. |
|---|
| Structure | CCN(CC)CC(=O)NC1=C(C)C=CC=C1C InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-(Diethylamino)-2',6'-acetoxylidide | ChEBI | | 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide | ChEBI | | alpha-Diethylamino-2,6-dimethylacetanilide | ChEBI | | Lidoderm | ChEBI | | Dentipatch | Kegg | | Xylocaine | Kegg | | a-Diethylamino-2,6-dimethylacetanilide | Generator | | Α-diethylamino-2,6-dimethylacetanilide | Generator | | Dilocaine | HMDB | | L-Caine | HMDB | | 2-2ETN-2MePhAcN | HMDB | | Astrazeneca brand OF lidocaine | HMDB | | Dalcaine | HMDB | | Jenapharm brand OF lidocanine hydrochloride | HMDB | | Lidocaine carbonate | HMDB | | Lidocaine hydrochloride | HMDB | | Lidocaine monohydrochloride | HMDB | | Lidocaine sulfate (1:1) | HMDB | | Lignocaine | HMDB | | Novocol brand OF lidocaine hydrochloride | HMDB | | Octocaine | HMDB | | Xylocitin | HMDB | | Lidocaine carbonate (2:1) | HMDB | | Strathmann brand OF lidocaine hydrochloride | HMDB | | Xyloneural | HMDB | | Lidocaine hydrocarbonate | HMDB | | Lidocaine monoacetate | HMDB | | Lidocaine monohydrochloride, monohydrate | HMDB | | Xylesthesin | HMDB |
|
|---|
| Chemical Formula | C14H22N2O |
|---|
| Average Molecular Weight | 234.3373 |
|---|
| Monoisotopic Molecular Weight | 234.173213336 |
|---|
| IUPAC Name | 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide |
|---|
| Traditional Name | lidocaine |
|---|
| CAS Registry Number | 137-58-6 |
|---|
| SMILES | CCN(CC)CC(=O)NC1=C(C)C=CC=C1C |
|---|
| InChI Identifier | InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17) |
|---|
| InChI Key | NNJVILVZKWQKPM-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as m-xylenes. These are aromatic compounds that contain a m-xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups at the 1- and 3-positions. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Benzene and substituted derivatives |
|---|
| Sub Class | Xylenes |
|---|
| Direct Parent | m-Xylenes |
|---|
| Alternative Parents | |
|---|
| Substituents | - M-xylene
- Tertiary aliphatic amine
- Tertiary amine
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Carboximidic acid derivative
- Carboximidic acid
- Organic nitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organooxygen compound
- Organonitrogen compound
- Amine
- Aromatic homomonocyclic compound
|
|---|
| Molecular Framework | Aromatic homomonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 68.5 °C | Not Available | | Boiling Point | 181 °C | Not Available | | Water Solubility | 0.59 g/L | Not Available | | LogP | 2.1 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 157.7 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 3.64 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.8249 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.33 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 72.5 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1087.5 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 204.6 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 139.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 157.2 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 48.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 293.3 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 376.4 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 150.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 727.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 273.5 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 877.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 210.6 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 260.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 273.2 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 332.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 97.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Lidocaine,1TMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C | 1721.5 | Semi standard non polar | 33892256 | | Lidocaine,1TMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C | 1852.1 | Standard non polar | 33892256 | | Lidocaine,1TMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C | 2218.2 | Standard polar | 33892256 | | Lidocaine,1TBDMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C(C)(C)C | 1991.0 | Semi standard non polar | 33892256 | | Lidocaine,1TBDMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C(C)(C)C | 2061.3 | Standard non polar | 33892256 | | Lidocaine,1TBDMS,isomer #1 | CCN(CC)CC(=O)N(C1=C(C)C=CC=C1C)[Si](C)(C)C(C)(C)C | 2348.3 | Standard polar | 33892256 |
|
|---|
| Disease References | | Colorectal cancer |
|---|
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
|
|
|---|
| General References | - Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee R, Rowland M: Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med. 1973 Apr;78(4):499-508. [PubMed:4694036 ]
- Khaliq W, Alam S, Puri N: Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004846. [PubMed:17443559 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
|
|---|